Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study.


Journal

The Lancet. Respiratory medicine
ISSN: 2213-2619
Titre abrégé: Lancet Respir Med
Pays: England
ID NLM: 101605555

Informations de publication

Date de publication:
12 2019
Historique:
received: 05 04 2019
revised: 08 08 2019
accepted: 05 09 2019
pubmed: 16 11 2019
medline: 2 7 2020
entrez: 16 11 2019
Statut: ppublish

Résumé

Staphylococcus aureus is the bacterium cultured most often from respiratory secretions of people with cystic fibrosis. Both meticillin-susceptible S aureus and meticillin-resistant S aureus (MRSA) can adapt to form slow-growing, antibiotic-resistant isolates known as small-colony variants that are not routinely identified by clinical laboratories. We aimed to determine the prevalence and clinical significance of S aureus small-colony variants and their subtypes among children with cystic fibrosis. The Small Colony Variant Staphylococcus aureus (SCVSA) study was a 2-year longitudinal study of children aged 6-16 years at five US cystic fibrosis centres, using culture methods sensitive for small-colony variants. Children were eligible if they had a documented diagnosis of cystic fibrosis and a minimum of two cystic fibrosis clinic visits and two respiratory cultures in the previous 12 months at enrolment. Participants attended clinic visits quarterly, at which respiratory tract samples were taken and measures of lung function (percentage of predicted forced expiratory volume in 1 s [FEV Between July 1, 2014, and May 26, 2015, we enrolled 230 children. Participants were followed-up for 2 years, with a mean of 6·4 visits (SD 1·14) per participant (range 2-9 visits) and a mean interval between visits of 3·94 months (SD 1·77). Across the 2-year period, S aureus small-colony variants were detected in 64 (28%) participants. Most (103 [56%] of 185) of the small-colony variants detected in these participants were thymidine dependent. Children with small-colony variants had significantly lower mean percentage of predicted FEV Infection with small-colony variants, and particularly thymidine-dependent small-colony variants, was common in a multicentre paediatric population with cystic fibrosis and associated with reduced lung function and increased risk of respiratory exacerbations. The adoption of small-colony variant identification and subtyping methods by clinical laboratories, and the inclusion of small-colony variant prevalence data in cystic fibrosis registries, should be considered for ongoing surveillance and study. The Cystic Fibrosis Foundation and the National Institutes of Health.

Sections du résumé

BACKGROUND
Staphylococcus aureus is the bacterium cultured most often from respiratory secretions of people with cystic fibrosis. Both meticillin-susceptible S aureus and meticillin-resistant S aureus (MRSA) can adapt to form slow-growing, antibiotic-resistant isolates known as small-colony variants that are not routinely identified by clinical laboratories. We aimed to determine the prevalence and clinical significance of S aureus small-colony variants and their subtypes among children with cystic fibrosis.
METHODS
The Small Colony Variant Staphylococcus aureus (SCVSA) study was a 2-year longitudinal study of children aged 6-16 years at five US cystic fibrosis centres, using culture methods sensitive for small-colony variants. Children were eligible if they had a documented diagnosis of cystic fibrosis and a minimum of two cystic fibrosis clinic visits and two respiratory cultures in the previous 12 months at enrolment. Participants attended clinic visits quarterly, at which respiratory tract samples were taken and measures of lung function (percentage of predicted forced expiratory volume in 1 s [FEV
FINDINGS
Between July 1, 2014, and May 26, 2015, we enrolled 230 children. Participants were followed-up for 2 years, with a mean of 6·4 visits (SD 1·14) per participant (range 2-9 visits) and a mean interval between visits of 3·94 months (SD 1·77). Across the 2-year period, S aureus small-colony variants were detected in 64 (28%) participants. Most (103 [56%] of 185) of the small-colony variants detected in these participants were thymidine dependent. Children with small-colony variants had significantly lower mean percentage of predicted FEV
INTERPRETATION
Infection with small-colony variants, and particularly thymidine-dependent small-colony variants, was common in a multicentre paediatric population with cystic fibrosis and associated with reduced lung function and increased risk of respiratory exacerbations. The adoption of small-colony variant identification and subtyping methods by clinical laboratories, and the inclusion of small-colony variant prevalence data in cystic fibrosis registries, should be considered for ongoing surveillance and study.
FUNDING
The Cystic Fibrosis Foundation and the National Institutes of Health.

Identifiants

pubmed: 31727592
pii: S2213-2600(19)30365-0
doi: 10.1016/S2213-2600(19)30365-0
pmc: PMC6924508
mid: NIHMS1546143
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1027-1038

Subventions

Organisme : NHLBI NIH HHS
ID : K24 HL141669
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK089507
Pays : United States

Investigateurs

Daniel J Wolter (DJ)
Frankline M Onchiri (FM)
Julia Emerson (J)
Mimi R Precit (MR)
Michael Lee (M)
Sharon McNamara (S)
Laura Nay (L)
Marcella Blackledge (M)
Ahmet Uluer (A)
David M Orenstein (DM)
Michelle Mann (M)
Wynton Hoover (W)
Ronald L Gibson (RL)
Jane L Burns (JL)
Xuan Qin (X)
Anne Marie Buccat (AM)
Alan Genatossio (A)
Nicoline Schaap (N)
Omalee Lopez (O)
Kathy Doan (K)
Robert Fowler (R)
Khadija Iken (K)
Kelsey Little (K)
Elizabeth Hartigan (E)
Kathryn Little (K)
Heather Hathorne (H)
Susan Keeling (S)
Katie Slaten (K)
Lucas R Hoffman (LR)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

Clin Microbiol Infect. 2013 Jan;19(1):77-84
pubmed: 22284387
Clin Microbiol Rev. 2016 Apr;29(2):401-27
pubmed: 26960941
Pediatr Pulmonol. 2015 May;50(5):431-40
pubmed: 25530325
Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5809-14
pubmed: 22451929
J Clin Microbiol. 1987 Jul;25(7):1258-61
pubmed: 3497170
Pediatr Pulmonol. 2015 Jun;50(6):552-9
pubmed: 25559432
J Clin Microbiol. 2007 Jan;45(1):168-72
pubmed: 17108072
J Bacteriol. 2008 Feb;190(3):834-42
pubmed: 17905979
Lancet. 1978 Jan 14;1(8055):104-5
pubmed: 74553
J Cyst Fibros. 2011 Sep;10(5):298-306
pubmed: 21719362
Clin Infect Dis. 2011 Sep;53(5):425-32
pubmed: 21844026
J Clin Microbiol. 2008 May;46(5):1832-4
pubmed: 18322058
Am J Respir Crit Care Med. 2009 Apr 15;179(8):734-5; author reply 735
pubmed: 19351873
Antimicrob Agents Chemother. 2015 Dec;59(12):7265-72
pubmed: 26369968
PLoS One. 2016 Nov 18;11(11):e0166220
pubmed: 27861524
JAMA. 2010 Jun 16;303(23):2386-92
pubmed: 20551409
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Sci Rep. 2018 Mar 1;8(1):3876
pubmed: 29497096
J Infect Dis. 1998 Apr;177(4):1023-9
pubmed: 9534977
Clin Infect Dis. 2013 Aug;57(3):384-91
pubmed: 23625938
Lancet. 1977 Nov 19;2(8047):1081
pubmed: 72988
Curr Opin Pulm Med. 2018 Nov;24(6):586-591
pubmed: 30113336
Pediatr Pulmonol. 2018 Nov;53(S3):S64-S74
pubmed: 30073802
Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19890-5
pubmed: 17172450
Nat Rev Microbiol. 2006 Apr;4(4):295-305
pubmed: 16541137
Am J Respir Crit Care Med. 2008 Oct 15;178(8):814-21
pubmed: 18669817
Antimicrob Agents Chemother. 2016 Jan 04;60(3):1725-35
pubmed: 26729501
Curr Microbiol. 2016 May;72(5):606-11
pubmed: 26821237
New Microbiol. 2015 Apr;38(2):235-43
pubmed: 25938748
J Pediatr. 2009 Feb;154(2):183-8
pubmed: 18822427
Pediatr Pulmonol. 2008 Nov;43(11):1117-1123
pubmed: 18846559
J Infect Dis. 2001 Feb 1;183(3):444-52
pubmed: 11133376
Chest. 2007 Aug;132(2):562-8
pubmed: 17646236
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Infect Genet Evol. 2014 Jan;21:515-22
pubmed: 23722021
J Clin Microbiol. 2003 Sep;41(9):4424-7
pubmed: 12958283
Pediatr Pulmonol. 2017 May;52(5):632-635
pubmed: 28328157
Pediatr Pulmonol. 2007 Jun;42(6):513-8
pubmed: 17469151

Auteurs

Daniel J Wolter (DJ)

Department of Pediatrics and Department of Microbiology, University of Washington, Seattle, WA, USA; Department of Pediatrics, Seattle Children's Hospital, Seattle, WA, USA.

Frankline M Onchiri (FM)

Department of Pediatrics, Seattle Children's Hospital, Seattle, WA, USA.

Julia Emerson (J)

Department of Pediatrics and Department of Microbiology, University of Washington, Seattle, WA, USA; Department of Pediatrics, Seattle Children's Hospital, Seattle, WA, USA.

Mimi R Precit (MR)

Department of Pediatrics and Department of Microbiology, University of Washington, Seattle, WA, USA.

Michael Lee (M)

Department of Pediatrics and Department of Microbiology, University of Washington, Seattle, WA, USA.

Sharon McNamara (S)

Department of Pediatrics, Seattle Children's Hospital, Seattle, WA, USA.

Laura Nay (L)

Department of Pediatrics, Seattle Children's Hospital, Seattle, WA, USA.

Marcella Blackledge (M)

Department of Pediatrics, Seattle Children's Hospital, Seattle, WA, USA.

Ahmet Uluer (A)

Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Department of Pediatrics, Brigham and Women's Hospital, Boston, MA, USA.

David M Orenstein (DM)

Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA, USA.

Michelle Mann (M)

Department of Pediatrics, Texas Children's Hospital, Houston, TX, USA.

Wynton Hoover (W)

Department of Pediatrics, University of Alabama, Tuscaloosa, AL, USA.

Ronald L Gibson (RL)

Department of Pediatrics, Seattle Children's Hospital, Seattle, WA, USA.

Jane L Burns (JL)

Department of Pediatrics and Department of Microbiology, University of Washington, Seattle, WA, USA; Department of Pediatrics, Seattle Children's Hospital, Seattle, WA, USA.

Lucas R Hoffman (LR)

Department of Pediatrics and Department of Microbiology, University of Washington, Seattle, WA, USA; Department of Pediatrics, Seattle Children's Hospital, Seattle, WA, USA. Electronic address: lhoffm@uw.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH